During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
